Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more
Starpharma Holdings Ltd (SPHRY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.121x
Based on the latest financial reports, Starpharma Holdings Ltd (SPHRY) has a cash flow conversion efficiency ratio of -0.121x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.23 Million) by net assets ($34.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Starpharma Holdings Ltd - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Starpharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Starpharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Starpharma Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stratus Properties Inc
NASDAQ:STRS
|
-0.043x |
|
TaTaTu SpA
PA:ALTTU
|
0.000x |
|
First Capital Inc
NASDAQ:FCAP
|
0.060x |
|
VAN DE VELDE (NACH AUFT.)
F:VO4
|
N/A |
|
d'Amico International Shipping S.A
OTCQX:DMCOF
|
0.060x |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
0.051x |
|
Power Solutions International Inc
PINK:PSIX
|
0.301x |
|
DONGJIANG ENVIRONMENTAL H
F:DGN
|
N/A |
Annual Cash Flow Conversion Efficiency for Starpharma Holdings Ltd (2014–2023)
The table below shows the annual cash flow conversion efficiency of Starpharma Holdings Ltd from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | $34.81 Million | $-13.53 Million | -0.389x | -42.92% |
| 2022-06-30 | $48.39 Million | $-13.16 Million | -0.272x | -14.43% |
| 2021-06-30 | $62.30 Million | $-14.81 Million | -0.238x | +30.90% |
| 2020-06-30 | $31.33 Million | $-10.78 Million | -0.344x | -40.99% |
| 2019-06-30 | $42.40 Million | $-10.34 Million | -0.244x | -27.43% |
| 2018-06-30 | $53.28 Million | $-10.20 Million | -0.191x | +31.13% |
| 2017-06-30 | $60.98 Million | $-16.95 Million | -0.278x | +22.85% |
| 2016-06-30 | $49.42 Million | $-17.81 Million | -0.360x | +0.59% |
| 2015-06-30 | $41.83 Million | $-15.16 Million | -0.363x | -21.73% |
| 2014-06-30 | $32.95 Million | $-9.81 Million | -0.298x | -- |